{"title":"对于未纳入临床试验的患者，多鲁曲韦和利福平的联合用药在艾滋病毒-霉菌感染二联症中是否同样有效和安全？临床实践案例","authors":"Sara Fontserè Recuenco , Rafael Luque-Márquez","doi":"10.1016/j.mcpsp.2024.100472","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Mycobacterial infections and HIV is still a relevant topic. Rifampicin complicates antiretroviral drugs management, influencing the prognostic of both conditions. Dolutegravir is a first option drug, but rifampicin diminishes its levels. Doubling dolutegravir doses until two weeks after completing rifampicin treatment has good results. Our goal is to confirm in our daily practice the efficacy and safety of this scheme.</div></div><div><h3>Methods</h3><div>Eighteen HIV patients were included with mycobacterial infections. Rifampicin was administered with dolutegravir twice a day as commented. Viral suppression and mycobacterial curation were analyzed until the end of the follow-up.</div></div><div><h3>Results</h3><div>Thirteen from 18 were men, 46 years (interquartile range [IQR]: 38–49), diagnosed of HIV or treated since 1.8 years (IQR: 0.1–12), presenting mainly disseminated mycobacterial infections (11 of 18 cases). From which completed follow-up, 91.6% achieved mycobacterial curation (11 of 12) and 92.9% viral load suppression (13 of 14).</div></div><div><h3>Conclusion</h3><div>The treatment of rifampicin with adjusted dolutegravir doses seems to be a proper combination even in severe immunosuppresed population.</div></div>","PeriodicalId":36921,"journal":{"name":"Medicina Clinica Practica","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"¿La combinación dolutegravir y rifampicina en los pacientes no incluidos en los ensayos clínicos es también eficaz y segura en el binomio VIH-infección micobacteriana? Casos de la práctica clínica\",\"authors\":\"Sara Fontserè Recuenco , Rafael Luque-Márquez\",\"doi\":\"10.1016/j.mcpsp.2024.100472\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Mycobacterial infections and HIV is still a relevant topic. Rifampicin complicates antiretroviral drugs management, influencing the prognostic of both conditions. Dolutegravir is a first option drug, but rifampicin diminishes its levels. Doubling dolutegravir doses until two weeks after completing rifampicin treatment has good results. Our goal is to confirm in our daily practice the efficacy and safety of this scheme.</div></div><div><h3>Methods</h3><div>Eighteen HIV patients were included with mycobacterial infections. Rifampicin was administered with dolutegravir twice a day as commented. Viral suppression and mycobacterial curation were analyzed until the end of the follow-up.</div></div><div><h3>Results</h3><div>Thirteen from 18 were men, 46 years (interquartile range [IQR]: 38–49), diagnosed of HIV or treated since 1.8 years (IQR: 0.1–12), presenting mainly disseminated mycobacterial infections (11 of 18 cases). From which completed follow-up, 91.6% achieved mycobacterial curation (11 of 12) and 92.9% viral load suppression (13 of 14).</div></div><div><h3>Conclusion</h3><div>The treatment of rifampicin with adjusted dolutegravir doses seems to be a proper combination even in severe immunosuppresed population.</div></div>\",\"PeriodicalId\":36921,\"journal\":{\"name\":\"Medicina Clinica Practica\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicina Clinica Practica\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2603924924000478\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicina Clinica Practica","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2603924924000478","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
¿La combinación dolutegravir y rifampicina en los pacientes no incluidos en los ensayos clínicos es también eficaz y segura en el binomio VIH-infección micobacteriana? Casos de la práctica clínica
Introduction
Mycobacterial infections and HIV is still a relevant topic. Rifampicin complicates antiretroviral drugs management, influencing the prognostic of both conditions. Dolutegravir is a first option drug, but rifampicin diminishes its levels. Doubling dolutegravir doses until two weeks after completing rifampicin treatment has good results. Our goal is to confirm in our daily practice the efficacy and safety of this scheme.
Methods
Eighteen HIV patients were included with mycobacterial infections. Rifampicin was administered with dolutegravir twice a day as commented. Viral suppression and mycobacterial curation were analyzed until the end of the follow-up.
Results
Thirteen from 18 were men, 46 years (interquartile range [IQR]: 38–49), diagnosed of HIV or treated since 1.8 years (IQR: 0.1–12), presenting mainly disseminated mycobacterial infections (11 of 18 cases). From which completed follow-up, 91.6% achieved mycobacterial curation (11 of 12) and 92.9% viral load suppression (13 of 14).
Conclusion
The treatment of rifampicin with adjusted dolutegravir doses seems to be a proper combination even in severe immunosuppresed population.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
